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Abstract
Introduction: To assess whether the value of CYFRA21-1 in the aspirates of ultrasonography-guided fine-needle aspiration
biopsy (US-FNAB) can contribute to improving the performances of US-FNAB in the diagnosis of axillary lymph node (LN)
metastasis in breast cancer patients.
Methods: US-FNAB was performed in 156 axillary LNs in 152 breast cancer patients (mean age: 51.4 years, range: 17–92
years). Concentrations of CYFRA21-1 were measured from washouts of the syringe used during US-FNAB. Tumor marker
concentrations, US-FNAB, intraoperative sentinel node biopsy (SNB), and surgical pathology results were reviewed and
analyzed. For comparison, the values of CEA and CA15-3 were also measured from washouts.
Results: Among the 156 LNs, 75 (48.1%) were benign, and 81 (51.9%) were metastases. Mean concentrations of CYFRA21-1
were significantly higher in metastasis compared to benign LNs (P,0.001). US-FNAB combined to CYFRA21-1 showed
significantly higher sensitivity, NPV, and accuracy compared to US-FNAB alone (all values P,0.05). All diagnostic indices of
US-FNAB combined to CYFRA21-1 were significantly higher compared to US-FNAB combined with CEA or CA15-3 (all
P,0.001). Of the 28 metastatic LNs which showed metastasis on SNB, CYFRA21-1 showed higher positive rate of 75.0% (CEA
or CA15-3:60.7%, P= 0.076).
Conclusion: Measuring CYFRA 21-1 concentrations from US-FNAB aspirates improves sensitivity, NPV, and accuracy of US-
FNAB alone, and may contribute to reducing up to 75.0% of unnecessary intraoperative SNB. Compared to CEA or CA15-3,
CYFRA21-1 shows significantly higher performances when combined to US-FNAB in the preoperative diagnosis of LN
metastasis in breast cancer patients.
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Introduction
Presence of metastatic lymph nodes in the axilla is the most
important prognostic factor in predicting outcome of patients
diagnosed with breast cancer [1–5] and preoperative diagnosis of
axillary or cervical lymph node (LN) metastasis directly affects the
type of surgery or treatment of the patient [6–8]. Ultrasound (US)-
guided fine-needle aspiration biopsy (US-FNAB) is a widely
accepted, easy but accurate diagnostic method that can be used in
evaluation of the axillary status and showed sensitivity up to
86.4%, specificity up to 100% in several studies [7,9–13].
Although sentinel node biopsy (SNB) is the method of choice in
evaluating axillary status, application of preoperative US-FNAB in
breast cancer patients who are expected to undergo surgical
treatment can reduce SNB, which can be both time consuming
and expensive [7,14]. The NCCN Guidelines for Breast Cancer
recommends US-FNAB for initial breast cancer staging [15], and
patients who have positive cytology results on preoperative US-
FNAB may do without SNB, but those showing clinically negative
LNs still need SNB for confirmation of the axillary status. Also,
with the development of surgical techniques and postoperative
patient management, administration of neoadjuvant chemother-
apy has steadily increased with the purpose for breast conserving
surgery, therefore, diagnostic methods that can provide accurate
information of the axillary status is urgently required. SNB is
a highly accurate method in axillary evaluation [16–17], but this is
an invasive procedure which itself can bring about surgical
complications or delayed onset of neoadjuvant chemotherapy
[17]. Using non-surgical diagnostic procedures may be of great
clinical benefit with simplifying or reducing aggressive surgery just
for diagnostic purposes.
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Recently, there had been some investigations using tumor
markers during evaluation of axillary LN metastasis [7,18–20].
One of them measured the concentrations of the tumor markers
carcinoembryonic antigen (CEA) and breast cancer antigen 15-3
(CA15-3) in axillary LN aspirates, and proved that measurements
of these tumor markers may be of additional help in preoperative
diagnosis of axillary LN metastasis in breast cancer patients [7].
Other studies used sentinel lymph node analysis using one-step
nucleic acid amplification (OSNA) has been proposed for
intraoperative staging of breast cancer [18,21], and in these
studies cytokeratin 19 (CK19) was considered as the most
appropriate marker due to its broad expression in breast
carcinomas [18,22]. Similarly, serum cytokeratin fragment 21-1
(CYFRA 21-1), which is known to react specifically with CK19
fragments, was recently proposed as an independent indicator of
prognosis in breast cancer [23–24]. Based on the concepts of these
studies, we investigated whether the CYFRA 21-1 concentrations
of US-FNAB aspirates can contribute to improving the perfor-
mances of US-FNAB in the diagnosis of axillary lymph node
metastasis in breast cancer patients.
Materials and Methods
Patients
The Institutional Review Board (IRB) of Severance Hospital,
Yonsei University approved of this study, and written informed
consent was obtained from the patients included.
From March 2008 to July 2010, 152 consecutive women
diagnosed with breast cancer who had undergone US-FNAB in
156 axillary LNs at our institution were included in this study
(Fig. 1). One-hundred thirty-eight (90.8%) patients had surgery
and subsequent SNB or axillary dissection, and the remaining 14
(9.2%) patients were diagnosed based on cytologic results of US-
FNAB. These 14 patients had not been operated on due to
presence of distant metastasis on other imaging studies (n = 11) or
benign cytology results in post-mastectomy patients who had
improved or no changes on follow-up imaging studies for at least 1
year (n = 3). Mean age of the patients were 51.4 years, ranging
from 17 to 92 years. Primary breast cancers diagnosed with biopsy
or surgery are as follows: invasive ductal carcinoma (n= 128),
ductal carcinoma in situ (n = 13), papillary carcinoma (n = 5),
invasive lobular carcinoma (n= 4), mucinous carcinoma (n = 1),
and tubular carcinoma (n= 1).
US and US-guided FNAB
US was performed by one of the seven board-certified
radiologists specializing in breast imaging (E.K.K, M.J.K.,
H.J.M., J.H.Y., and J.S.C), each of whom had various experiences
in breast imaging and biopsy (range: 1–11 years), using a 5-12-
MHz (HDI 5000; Philips-ATL, Bothell, WA) or 5-12-MHz (iU22;
Philips Medical Systems) linear array transducer. Suspicious US
features suggestive of metastasis in the axillary LNs were as follows;
loss of fatty hilum, cortical thickening measuring more than 3 mm
in thickness, irregular or round shape, extracapsular tumor
extension, markedly hypoechogenicity of the cortex, and promi-
nent peripheral blood flow on US Doppler [3,7]. Size was
measured as the maximum diameters on either transverse or
longitudinal scans.
US-FNAB was performed with a 23-gauge needle attached to
a 2-mL disposable syringe using freehand technique. Each LN was
aspirated at least twice. Material aspirated were immediately
expelled onto glass slides and placed in 95% alcohol for
Papanicolaou staining. The remaining contents in the needle
and syringe from the first aspiration were rinsed with 1 mL of
saline. Concentrations of CEA, CA15-3 and CYFRA 21-1 were
measured individually from these washouts. Washouts from the
second aspiration were sent for cell block processing.
Five cytopathologists (with 1–15 years of experience) interpreted
the FNAB specimen. The cytologic results were divided into two
categories based on the reports. Cytologic results showing
metastasis from breast cancer or atypical cells were considered
positive. Reactive hyperplasia or benign lymphadenopathy, results
that are non-related to breast cancer were considered negative.
Reports showing insufficient material for specific diagnosis were
considered negative, as proposed in other reports [7,25–27].
Tumor Marker Analysis
Tumor marker concentrations were analyzed with an automat-
ed immunoanalyzer system with chemiluminescent immunoassays
for CEA (Unicel DXi800; Beckman Coulter, Inc, USA), CA 15-3
(VITROS 3600; Ortho-Clinical Diagnostics, USA), and CYFRA
21-1 (E411; Roche Diagnostics, Germany). A noncompetitive
immunometric sandwich assay format containing monoclonal
antibodies for each tumor marker was used with the immunoassay
reagents (AccessCEA for CEA, Vitros CA 15-3 for CA 15-3,
CYFRA 21-1 for CYFRA 21-1).
Surgical Procedures for Diagnosis of Axillary Lymph Node
Metastasis
Figure 1 shows the flow diagram for diagnosis, surgical
management, and pathology results of axillary LN metastasis in
the patients included in our study. Breast surgery including
evaluation of the axillary nodal status was performed by one of the
two breast surgeons with 16 and 9 years of experience in breast
surgery, respectively. Axillary LNs with positive cytology on US-
FNAB directly underwent axillary node dissection, without
sentinel node biopsy (SNB). Axillary LNs with negative cytology
on US-FNAB underwent SNB, and according to the SNB results,
axillary node dissection was performed on patients showing
positive histology on SNB, while no further nodal dissection was
done if SNB showed negative histology, with the exception of
patients with neoadjuvant chemotherapy [7].
Data and Statistical Analysis
Histopathologic results from subsequent surgery or clinical
evidence during follow-up were regarded as standard reference.
Among the LNs with surgical confirmation, aspirated LNs were
correlated by the location seen during surgery.
Student’s t-test was used in comparison of mean size between
benign and metastatic LNs. Shapiro-Wilk test and Wilcoxon rank-
sum test was used in comparison of the concentrations of each
tumor marker between benign and metastatic groups.
Sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), and accuracy were assessed based on
standard reference for US-FNAB alone, US-FNAB combined with
CYFRA 21-1, and US-FNAB combined with CEA or CA15-3.
Logistic regression method was used in estimation of cutoff
concentration levels of tumor markers. Generalized estimating
equation (GEE) method or weighted least square (WLS) method
was used was used in comparison of diagnostic performances
between US-FNAB alone and US-FNAB combined with CYFRA
21-1, and US-FNAB combined with CYFRA 21-1 and US-FNAB
combined with CEA or CA15-3. Fisher’s exact test was used in
comparing performances among tumor markers in LNs which had
undergone intraoperative SNB.
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Statistical analyses were performed with SAS, version 9.1.3 for
Windows (SAS Institute, Cary, NC). P,0.05 was considered to
indicate statistical significance.
Results
Of the 156 axillary LNs in the 152 patients included, 75 (48.1%)
were benign, and 81 (51.9%) were metastases. Mean size of the
156 axillary LNs was 13.0766.38 mm, ranging from 1.00 to
35.00 mm. Among the positive LNs, 69 were diagnosed with
surgery, while the remaining 12 were diagnosed with cytology
alone, due to the presence of distant metastasis (n = 11) or plans for
chemotherapy or radiation therapy than surgery (n = 1).
Of the 69 metastatic LNs diagnosed with surgery, 32 (49.2%)
underwent SNB prior to axillary LN dissection, among which 28
showed metastatic results (Fig. 2a). Of the 75 benign LNs, 70
(93.3%) underwent SNB, all showing benign results (Fig. 2b).
Among the 75 benign LNs, 4 were diagnosed as benign based on
cytology only. All 4 LNs in 3 patients were followed regularly with
US for at least 1 year, and showed decreased size or no changes on
follow-up images.
Comparison of Size and Concentrations of Tumor
Markers
Table 1 shows the comparison of mean size and mean
concentrations of the tumor markers between the benign or
metastatic LNs. Mean size of the LNs was significantly larger in
metastasis compared to benign, 14.4367.34 mm to
11.6064.78 mm (P=0.001). Mean concentrations of CEA,
CA15-3 and CYFRA 21-1 showed significantly higher levels in
metastatic LNs compared to the benign LNs (all markers P,0.001,
respectively).
Comparison of Diagnostic Performances of US-FNAB
Combined with CYFRA 21-1 and US-FNAB Alone, US-
FNAB Combined with CEA or CA15-3
Cytology results from US-FNAB in the 156 LNs included are as
follows: inadequate or insufficient material for diagnosis in 6
(3.9%), benign in 86 (55.1%), and metastasis in 64 (41.0%).
Diagnostic performances of CEA, CA15-3 and CYFRA 21-1
alone, US-FNAB, US-FNAB combined with CYFRA 21-1, and
US-FNAB combined with CEA or CA15-3 are summarized in
Table 2. Sensitivity, specificity, PPV, NPV, and accuracy of US-
FNAB alone was 79.0%, 100.0%, 100.0%, 81.5%, and 89.1%,
respectively. Among the LNs proven as metastasis on surgery, 17
were diagnosed as inadequate or benign on US-FNAB, showing
false-negative rate of 21.0% (17/81).
Optimal cutoff concentration values of the three tumor markers
calculated from logistic regression methods were as follows: CEA
0.58 ng/mL, CA15-3 2.8 IU/mL, and CYFRA 21-1 1.93 ng/
mL, respectively. US-FNAB combined to CYFRA 21-1 showed
significantly improved sensitivity, NPV and accuracy compared to
US-FNAB alone, 91.4% to 79.0% (P=0.001), 91.1% to 81.5%
(P,0.001), and 93.6% to 89.1% (P=0.001), respectively, but
decreased PPV, 96.1% to 100.0% (P=0.002). Specificity of US-
FNAB combined to CYFRA 21-1 was lower than US-FNAB
alone, 96.0% to 100.0%, but without significance (P=0.085). For
comparison with a previous study [7], performances of US-FNAB
with CEA or CA15-3 was calculated and compared to US-FNAB
with CYFRA 21-1, showing significantly higher values in all
diagnostic indices in US-FNAB combined with CYFRA 21-1 (all
P,0.001).
Figure 2 summarizes the results of US-FNAB, SNB, and
concentrations of the three tumor markers. Among the 81
metastatic LNs, 17 had inadequate or benign cytology results on
US-FNAB, among which all 17 were diagnosed as positive on
Figure 1. Diagram of diagnosis, surgical management and pathologic diagnosis of the axillary LNs in 152 patients with breast
cancer. Note: patient numbers are in parentheses ALND: axillary lymph node dissection. *: ALND performed due to metastatic results on
preoperative US-FNAB cytology, All 4 patients had received neoadjuvant chemotherapy, and final pathology showed micrometastatic foci within the
lymph nodes.
doi:10.1371/journal.pone.0057248.g001
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SNB. Eight (53.3%) of the 15 LNs showing benign cytology had
CYFRA 21-1 concentrations categorized as positive, while only 2
(13.3%) and 3 (20.0%) LNs were categorized as positive when
using CEA and CA15-3 concentration levels. Both LNs showing
inadequate cytology had CYFRA 21-1 concentrations categorized
Figure 2. Diagram of US-FNAB, SNB and tumor markers in proven metastatic (a) and benign (b) lymph nodes.
doi:10.1371/journal.pone.0057248.g002
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as positive, while none of the LNs were positive for CEA and one
LN was positive for CA15-3.
Correlation of Sentinel Node Biopsy with Tumor Marker
Concentrations
Table 3 shows the correlation of the 102 axillary LNs with SNB
to the concentrations of CEA or CA15-3 and CYFRA 21-1.
Among the 28 metastatic LNs diagnosed as metastasis on SNB,
CYFRA 21-1 showed higher positive rates compared to CEA or
CA15-3, 21 (75.0%) to 17 (60.7%), respectively, but without
statistical significance (P=0.076). All 4 metastatic LNs diagnosed
as benign on SNB showed positive results in CEA or CA15-3 and
CYFRA 21-1.
Of the 70 benign LNs diagnosed as benign SNB, CYFRA 21-1
showed significantly higher negative results compared to CEA or
CA15-3, 95.7% to 81.4%, respectively (P=0.021).
Discussion
US-FNAB is a common and popularly used diagnostic method
in predicting nodal status of breast cancer patients [4,6,9–11,26].
Although not as confirmative as surgical pathology, with fine-
needle aspiration surgeons can predict in detail what to expect on
Table 1. Mean size and concentrations of CA125, CA19-9, and CYFRA 21-1 in US-FNAB aspirates of the 156 axillary lymph nodes.
Pathology P
Benign (n =75) Malignant (n=81)
Mean LN Size (mm) 11.6064.78 14.4367.34 0.001
CEA (ng/mL) Mean 6 SD 0.1260.16 26.146101.27 ,0.001
Median 0.03 0.31
Min/Max 0.00/0.65 0.00/745.29
CA15-3 (IU/mL) Mean 6 SD 2.2362.00 20.87687.20 ,0.001
Median 1.80 3.30
Min/Max 0.50/17.10 0.50/729.0
CYFRA21.1 (ng/mL) Mean 6 SD 1.1860.75 815.3061375.17 ,0.001
Median 0.98 94.31
Min/Max 0.47/6.32 0.69/4923.0
doi:10.1371/journal.pone.0057248.t001
Table 2. Diagnostic performances of CEA, CA15-3 and CYFRA 21-1 at cutoff levels, US-FNAB alone, and US-FNAB combined with
each tumor marker.
Cutoff level Sensitivity P Specificity P PPV P NPV P Accuracy P
CEA 0.58 ng/mL) 43.2 (35/81) – 98.7 (74/75) – 97.2 (35/36) – 61.7 (74/120)– 69.9 (109/
156)
–
CA15-3 2.8 (IU/mL) 59.3 (48/81) – 82.7 (62/75) – 78.7 (48/61) – 65.3 (62/95) – 70.5 (110/
156)
–
CYFRA 21-1 1.93(ng/mL) 87.7 (71/81) – 96.0 (72/75) – 96.0 (71/74) – 87.8 (72/82) – 91.7 (143/
156)
–
US-FNAB – 79.0 (64/81) – 100.0 (75/75)– 100.0 (64/64)– 81.5 (75/92) – 89.1 (139/
156)
–
US-FNAB &
CYFRA 21-1
– 91.4 (74/81) 0.001{ 96.0 (72/75) 0.085{ 96.1 (74/77) 0.002{ 91.1 (72/79) ,0.001{ 93.6 (146/
156)
0.001{
US-FNAB & CEA
or CA15-3
– 86.4 (70/81) ,0.001* 81.3 (61/75) ,0.001* 83.3 (70/84) ,0.001* 84.7 (61/72) ,0.001* 84.0 (131/
156)
,0.001*
–Raw data in parentheses,
{values compared to US-FNAB,
*values compared to US-FNAB combined with CYFRA 21-1.
doi:10.1371/journal.pone.0057248.t002
Table 3. Correlation of the 102 axillary LNs with sentinel
node biopsy to concentrations of CEA, CA15-3 and CYFRA
21.1.
Final SNB
CEA or
CA15-3
CYFRA
21-1
N Negative Positive Negative Positive
Benign B 70 57(81.4) 13 (18.6) 67 (95.7) 3 (4.3)
70 M 0 – – – –
Metastatic B 4 0 (0.0) 4 (100.0) 0 (0.0) 4 (100.0)
32 M 28 11 (39.3) 17 (60.7) 7 (25.0) 21 (75.0)
Percentages are in parentheses.
doi:10.1371/journal.pone.0057248.t003
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surgical pathology based on the cytology results. But, US-FNAB
has its limitations in that false-negative results can exist [1], and
therefore, patients who are diagnosed as negative or non-
diagnostic on cytology alone need additional sentinel node biopsy
procedures during surgery to decide upon axillary node dissection,
which is both time consuming and expensive. Also, performing
axillary dissection on all patients with breast cancer can lead to
increased morbidity from various surgical complications. Various
efforts have been made to improve the performances of pre-
operative US-FNAB [1,7,9], including measurement of tumor
markers used in the management of breast cancer patients such as
CEA and CA 15-3 from US-FNAB aspirates [7].
In addition to CEA and CA15-3, CYFRA 21-1 (derived from
the words cytokeratin fragment 21.1), the most sensitive tumor
marker used in monitoring non-small cell lung cancer [28-29], has
been reported to be detected in the peripheral blood from patients
with metastatic breast cancer and proposed to be used in
monitoring disease relapse and treatment response in breast
cancer patients [23–24,30]. Also, studies analyzing CK19 in the
intraoperative diagnosis of metastatic axillary LNs in breast cancer
patients using molecular diagnostic devices [31–32], or rapid
molecular-based assay during intraoperative SNB [18,33–34],
showed high concordance rate to histopathology reducing delayed
secondary surgical procedures. Since US-FNAB cytology is an
excellent diagnostic tool in the preoperative diagnosis of axillary
LNs in breast cancer patients [6,8,11–13], adding tumor marker
analysis to the washouts obtained from US-FNAB procedures has
its strong points in that more information can be obtained by this
method without addition invasive procedures, in short, both
cytology and tumor marker status can be obtained with a single
US-FNAB session. Based on this, we investigated the role of
CYFRA 21-1 concentrations from US-FNAB aspirates in the
diagnosis of metastatic axillary LNs, adapting the concept of
measuring the CEA and CA15-3 concentrations from FNAB
aspirates of axillary LNs from a previous study [7].
At the present date, administration of neoadjuvant chemother-
apy is increasing rapidly with the expectation of breast conserving
surgery, even in patients with large breast masses [35]. Acknowl-
edgement of the axillary nodal status is critical in both
management and prognosis of these patients [14], and some
studies recommend invasive SNB prior to neoadjuvant chemo-
therapy for more accurate evaluation of axillary status [16–17].
Claiming that SNB should be performed prior to neoadjuvant
chemotherapy may be due to the false-negative and inadequate
results of US-FNAB, a major limitation of this procedure
[7,9,14,27,36]. Our results show that combining CYFRA 21-1
concentrations to US-FNAB can overcome this limitation some-
what; according to the results of our study, US-FNAB combined to
CYFRA 21-1 can accurately diagnose axillary LN metastasis with
high sensitivity of 91.4%, significantly higher than that of US-
FNAB alone, 79.0%. Adding CYFRA 21-1 to US-FNAB
significantly improves the sensitivity of US-FNAB, and may prove
to be beneficial in the management of 1) patients who are
scheduled for surgery in means of reducing SNB, and 2) patients
who need histopathologic confirmation of axillary nodal status
prior to neoadjuvant chemotherapy, especially without applying
additional invasive surgical procedures such as SNB for diagnosis.
In addition, for comparison to a previous study using CEA and
CA15-3 in the diagnosis of metastatic axillary LNs [7], we
calculated the diagnostic performances of US-FNAB combined
with CEA or CA15-3. When comparing US-FNAB combined
with CYFRA 21-1 to US-FNAB with CEA or CA15-3, all
diagnostic indices were significantly higher in CYFRA 21-1. These
results further support the efficacy of using CYFRA 21-1 in the
diagnosis of metastatic axillary LNs over CEA or CA15-3, being
able to get better performances with the analysis of one tumor
marker compared to the combined usage of two. Also, as reported
in a study on comparing molecular analysis and histopathology for
axillary LN staging in primary breast cancer when compared to
molecular detection using OSNA assay [37], histopathology of
single tissue sections significantly underestimated the frequency of
axillary LN metastasis. In contrast, when using OSNA assay, all
the metastatic LNs which were underestimated on single tissue
sections were diagnosed as metastasis. If cytology specimen are
obtained from various areas of the targeted axillary LN during
US-FNAB procedures by changing angles of the needle after skin
penetration, even if gross cytologic detection of the metastatic cell
itself is difficult, CYFRA 21-1 concentrations may prove other-
wise. CYFRA 21-1 may not only improve the diagnostic
performances of US-FNAB, but may have a role in enhancing
the performances of less experienced performers who are more
likely to have insufficient or ambiguous cytology results.
False-negative results and inadequate sampling of US-FNAB
arouses confusion and frustration to clinicians and patients
[7,9,14,27,36]. When applying tumor marker concentrations, 8
of 15 metastatic LNs with benign cytology showed elevated
concentrations of CYFRA 21.1, while 2 and 3 LNs showed
elevated concentrations in CEA and CA15-3. Also, of the 2
metastatic LNs with inadequate cytology, both LNs had elevated
concentrations of CYFRA 21-1, while none of them had elevated
levels of CEA and one had elevated CA15-3 concentration levels.
This shows the relative sensitivity of CYFRA 21-1 in detecting
metastatic LNs compared to US-FNAB alone and CEA or CA15-
3. In addition, we evaluated the diagnostic performances of tumor
markers combined to US-FNAB among lesions with intraoperative
SNB to see whether tumor markers help in reducing SNB
procedures during surgery. Of the 28 metastatic LNs with
metastatic results on SNB, CYFRA 21-1 showed higher positive
results compared to CEA or CA15-3, 75.0% to 60.7%, re-
spectively. When using CYFRA 21-1 concentrations, nearly 75%
patients would be saved from unnecessary SNB, and would able to
proceed directly into axillary node dissection. Also, CYFRA 21-1
showed significantly higher negative results compared to CEA or
CA15-3 among the proven-benign LNs with benign SNB results,
95.7% to 81.4%, implying less false-positive results among benign
LNs.
This study has several limitations. First, a limited number of
axillary LNs were included in this study. Second, whether elevated
levels of CYFRA 21-1 have effect on the patient’s outcome or
prognosis has not yet been verified. Prospective studies with long-
term evaluation are anticipated in the future. Third, since this
study was conducted on a clinical basis, all patients included were
diagnosed with breast cancer, and our results were not validated
by a negative control group, i.e., those who were not diagnosed
with breast cancer. In a recent study, concentrations of CEA,
CA15-3, and CYFRA 21-1 in US-FNAB aspirates among the non-
metastatic LNs ranged from 0.02–1.90 (ng/mL or U/mL) [38],
values which may substitute the negative control group of our
study.
In conclusion, measuring CYFRA 21-1 concentrations from
US-FNAB aspirates improves sensitivity, PPV, NPV, and accuracy
of US-FNAB alone, and may contribute to reducing up to 75.0%
of unnecessary intraoperative SNB. Compared to CEA or CA15-
3, CYFRA 21-1 shows significantly higher performances when
combined to US-FNAB in the preoperative diagnosis of LN
metastasis in breast cancer patients.
CYFRA 21-1 in Node Metastasis of Breast Cancer
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